Abstract: A method for the purification of a culture filtrate resulting from the fermentation of an organism of the species Mucor miehei involves the selective adsorption of the microbial rennet present in the culture filtrate by a blue dye affinity ligand with subsequent elution of the adsorbed microbial rennet to provide it in a purified form.
Abstract: An Escherichia coli chromosomal DNA segment is engineered for controllable excision and loss from the E. coli cell population. The DNA segment has a gene determining a function that is lost in the absence of that chromosomal segment. Specifically, the segment includes a pair of lambdoid phage att sites positioned at opposite ends thereof, and a gene encoding the function. The E. coli cell includes DNA encoding lambdoid phage int and xis, positioned for transcription under control of an external stimulus. By excising the chromosomal DNA segment once a desired cell population is achieved, cell growth and diversion of intermediates from a desired fermentation product are diminished or avoided.
Type:
Grant
Filed:
February 13, 1985
Date of Patent:
May 10, 1988
Assignees:
Biotechnica International, Inc., H. J. Heinz Company
Inventors:
Keith C. Backman, Ramaswamy Balakrishnan
Abstract: The present invention provides a process for the preparation of digitalis antibodies in which appropriate mammals are immunized with a digoxin bound to protein, the animal serum is obtained, the immune globulin-containing protein fraction is separated in known manner, the immunologically-active globulins are adsorbed on an immunologically-active column and separated from the other proteins, the antibodies are again eluted from the column and the Fab fractions are split with papain and purified, wherein, as immunologically-active adsorbent, there is used an inorganic matrix of large surface area to which digitoxin aldehyde is bound via a spacer which cannot be split with papain and the splitting off of the Fab fraction from the antibodies is carried out on the matrix.The present invention also provides digitalis antibodies obtained by this process, which antibodies can be used for the therapy of digitalis intoxications and for preparing immunological reagents for the determination of digitalis glycosides.
Type:
Grant
Filed:
December 19, 1983
Date of Patent:
May 3, 1988
Assignee:
Boehringer Mannheim GmbH
Inventors:
Hans-Georg Batz, Herbert Jungfer, Helmut Lenz, Albert Roder
Abstract: A method of producing enzymatically active eucaryotic superoxide dismutase or an analog thereof in a bacterial cell which contains and is capable of expressing a DNA sequence encoding the superoxide dismutase or analog thereof comprising maintaining the bacterial cell under suitable conditions and in a suitable production medium. The production medium is supplemented with an amount of Cu++ so that the concentration of Cu++ in the medium is greater than about about 2 ppm.The invention also concerns methods of recovering purified enzymatically active eucaryotic superoxide dismutase or analogs from bacterial cells producing the superoxide dismutase or analog.
Type:
Grant
Filed:
August 27, 1984
Date of Patent:
May 3, 1988
Assignee:
BIO-Technology General Corp.
Inventors:
Jacob R. Hartman, Dov Kanner, Daniel Bartfeld
Abstract: This invention relates to antibody-metal ion complexes having a metal ion coordinately bound to a compatible chelator covalently bound to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody-metal ion complexes. Therapeutic and in vitro and in vivo diagnostic methods utilizing such antibody-metal ion complexes are described.
Type:
Grant
Filed:
August 31, 1984
Date of Patent:
May 3, 1988
Assignee:
Cytogen Corporation
Inventors:
Vernon L. Alvarez, John D. Rodwell, Chyi Lee, John W. F. Goers, Richard C. Siegel, Thomas J. McKearn
Abstract: Methods and compositions are provided for the recombinant synthesis of the tumor growth factor-.alpha. precursor and its fragments. These are useful in therapy and diagnosis, as are antibodies raised by immunization with the tumor growth factor-.alpha. precursor and its fragment.
Abstract: The present invention comprises improved derivatives of the tryptophan operon useful for expressing fused gene products in E. coli and relate organism. Two of the improved derivatives disclosed are encoded on 0.43 and 0.55 kb EcoRI restriction fragments from plasmids pCZ20 and pLEBGH2 (in strains NRRL B-15881 and NRRL B-15882), respectively. The modified derivatives have been placed on recombinant DNA cloning and expression vectors. A variety of expression vectors have been constructed that drive expression of fused gene products. Two novel gene sequences, encoding insulin-like growth factors I and II, have been expressed with the modified tryptophan operon system.
Type:
Grant
Filed:
September 27, 1984
Date of Patent:
April 19, 1988
Assignee:
Eli Lilly and Company
Inventors:
Ramamoorthy Belagaje, Janet K. Epp, JoAnn Hoskins, Hansen M. Hsiung, George L. Long, Brigitte E. Schoner
Abstract: This invention describes the discovery of a novel phenomena in retrovirus transcription, namely transcriptional trans-activation. Described herein are novel trans-acting factors which may be employed to enhance the production of heterologous genes. Described is a novel trans-acting directing gene, designated herein as the "luk" gene and the 35,000 to 45,000, more specifically about 42,000 dalton molecular weight protein encoded thereby.The present invention demonstrates the LTR elements of HTLV can function as transcriptional promoters for heterologous genes on both unintegrated and integrated DNA. In general, the HTLV-1 LTR is a stronger promoter than is the HLTV-II LTR in its requirements for cellular and/or viral trans-acting factors in order to function efficiently. HTLV infection results in the production of trans-acting factors that dramatically increase the rate of HTLV LTR-promoted transcription.
Type:
Grant
Filed:
May 25, 1984
Date of Patent:
April 19, 1988
Assignee:
Dana Farber Cancer Institute
Inventors:
William A. Haseltine, Joseph G. Sodrowski, Craig A. Rosen
Abstract: A labeled nucleic acid probe comprising (a) a nucleic acid component, (b) a nucleic acid-binding ligand photochemically linked to the nucleic acid component, and (c) a label chemically linked to the nucleic acid-binding ligand. The label can be a specifically bindable ligand such as a hapten or biotin, an enzyme such as a .beta.-galactosidase or horse radish peroxidase, a fluorescent radical, a phycobiliprotein, a luminescent radical, or a radioisotope. The probe can be used in assays of nucleic acids, taking advantage of the ability of the nucleic acid component to hybridize.
Type:
Grant
Filed:
May 18, 1984
Date of Patent:
April 12, 1988
Assignee:
Molecular Diagnostics, Inc.
Inventors:
Nanibhushan Dattagupta, Donald M. Crothers
Abstract: Candida albicans has been transformed by the insertion of a plasmid comprising a fragment of DNA from Candida albicans containing the intact ADE 2 gene.
Abstract: A strain of Actinomadura sp., NRRL 15758, is capable of producing the CL-1724 complex of antibiotic substances in isolable quantities under conditions of aerobic fermentation in a culture medium containing assimilable sources of carbon and nitrogen.
Abstract: A method is provided of producing variant plant varieties of Lycopersicon spp. by tissue culture techniques employing 6-benzyladenine at high concentrations. The technique produces phenotypic variants that are the result of heritable nuclear genetic changes.
Abstract: A recombinant DNA molecule, a portion of which includes a vector whose replication is initiated independently of the temperature-sensitive mutant gene of a temperature-sensitive mutant strain of the genus Bacillus as host is introduced into the host. The host is then cultured at a temperature which does not completely inhibit chromosomal DNA replication. By this process, the recombinant DNA molecule can be stabilized in the host and its expression can be enhanced.
Type:
Grant
Filed:
August 18, 1986
Date of Patent:
March 15, 1988
Assignees:
Agency of Industrial Science and Technology, Ministry of International Trade and Industry
Abstract: A process for the production of aminoglycoside antibiotics using fused protoplasts derived from streptomyces. The cells are precultured in a medium containing sucrose, calcium and magnesium salts. Protoplasts are formed and then fused. The fused protoplasts are regenerate and antibiotic producing ability is screened for. The regenerate cells produced an antibiotic complex of modified composition or demonstrated increased or reduced antibiotic productivity compared to the fusion partners.
Type:
Grant
Filed:
May 16, 1984
Date of Patent:
March 8, 1988
Assignee:
Biogal Gyogyszergyar
Inventors:
Lajos Ferenczy, Antal Mai, Istvan Ott, Gabor Ambrus, Tibor Lang
Abstract: L-Glutamic acid is produced in a high yield by cultivating an L-glutamic acid-producing microorganism which requires oleic acid but does not require biotin for growth in a culture medium containing an oleic acid compound and a biotin compound of no less than 100 .mu.g/liter as biotin, with carbohydrate and acetic acid as carbon sources being maintained in a weight ratio of about 80:20 through about 40:60.
Abstract: Biological compositions are decontaminated by treatment with furocoumarin derivatives and irradiation under particular conditions in which the proteins retain their original physiological activities and any pathogenic microorganisms and polynucleotide fragments thereof are rendered inactive. It has been found that reduction of the amount of dissolved oxygen in the treatment solution substantially inhibits denaturation of the proteins.
Abstract: This invention provides a process for producing nylon 6,6 salt which involves bioconversion of toluene to muconic acid in the presence of hexamethylenediamine to yield hexamethylenediamine muconate salt. Hydrogenation of this salt provides an aqueous solution of the desired hexamethylenediamine adipate salt.
Type:
Grant
Filed:
January 13, 1983
Date of Patent:
February 16, 1988
Assignee:
Celgene Corporation
Inventors:
Sol J. Barer, Peter C. Maxwell, Jih-Han Hsieh
Abstract: L-histidine is produced by culturing, in a nutrient medium, an L-histidine producing mutant microorganism belonging to the genus Corynebacterium. The mutant is resistant to a precursor for ubiquinone biosynthesis. L-histidine is accumulated in the culture liquor and is recovered therefrom.
Abstract: A c-Kirsten ras oncogene has been isolated from a human lung tumor cell line. This c-Kirsten ras has a mutation in codon 61 of the second coding exon and is capable of transforming NIH/3T3 mouse fibroblast cells to tumorigenic cells.
Type:
Grant
Filed:
January 19, 1984
Date of Patent:
February 16, 1988
Assignee:
Research Foundation of State University of New York
Inventors:
Manuel Perucho, Hirofumi Nakano, Fumiichiro Yamamoto, Craig Neville
Abstract: A process is disclosed for the construction of synthetic peptides corresponding to amino acid sequences of 55-, 59-, 60-, 67-kilodalton keratin proteins. These synthetic peptides make possible the development of monospecific antisera for individual keratin proteins. The process involves preparing cDNA libraries and reducing the amino sequences of cDNA clones.
Type:
Grant
Filed:
September 25, 1984
Date of Patent:
February 2, 1988
Assignee:
The United States of America as represented by the Secretary, Dept. of Health & Human Services
Inventors:
Stuart H. Yuspa, Dennis R. Roop, Peter M. Steinert